CoChat
Sign Up
Cited by 27Malaria Research and ControlImmunotherapy and Immune Responsesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Preclinical development of a stabilized RH5 virus-like particle vaccine that induces improved antimalarial antibodies

Open access
King, Lloyd D.W., Pulido, David, Barrett, Jordan R., Davies, Hannah, Quinkert, Doris, Lias, Amelia M., Silk, Sarah E., Pattinson, David J., Diouf, Ababacar, Williams, Barnabas G., McHugh, Kirsty, Rodrigues, Ana, Rigby, Cassandra A., Strazza, Veronica, Suurbaar, Jonathan, Rees-Spear, Chloe, Dabbs, Rebecca A., Ishizuka, Andrew S., Zhou, Yu, Gupta, Gaurav, Jin, Jing, Li, Yuanyuan, Carnrot, Cecilia, Minassian, Angela M., Campeotto, Ivan, Fleishman, Sarel J., Noe, Amy R., MacGill, Randall S., King, C. Richter, Birkett, Ashley J., Soisson, Lorraine A., Long, Carole A., Miura, Kazutoyo, Ashfield, Rebecca, Skinner, Katherine, Howarth, Mark R., Biswas, Sumi, Draper, Simon J.·2024·Cell Reports Medicine
DOI 10.1016/j.xcrm.2024.101654PMC PMC11293324

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Abstract The development of a highly effective vaccine against the pathogenic blood-stage infection of human malaria will require a delivery platform that can induce an antibody response of both maximal quantity and functional quality. One strategy to achieve this includes presenting antigens to the immune system on virus-like particles (VLPs). Here we sought to improve the design and delivery of the blood-stage Plasmodium falciparum reticulocyte-binding protein homolog 5 (RH5) antigen, which is currently in a Phase 2 clinical trial as a full-length soluble protein-in-adjuvant vaccine candidate called RH5.1/Matrix-M™. We identify disordered regions of the full-length RH5 molecule induce non-growth inhibitory antibodies in human vaccinees, and a re-engineered and stabilized immunogen that includes just the alpha-helical core of RH5 induces a qualitatively superior growth-inhibitory antibody response in rats vaccinated with this protein formulated in Matrix-M™ adjuvant. In parallel, bioconjugation of this new immunogen, termed “RH5.2”, to hepatitis B surface antigen VLPs using the “plug-and-display” SpyTag-SpyCatcher platform technology also enabled superior quantitative antibody immunogenicity over soluble antigen/adjuvant in vaccinated mice and rats. These studies identify a new blood-stage malaria vaccine candidate that may improve upon the current leading soluble protein vaccine candidate RH5.1/Matrix-M™. The RH5.2-VLP/Matrix-M™ vaccine candidate is now under evaluation in Phase 1a/b clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xcrm.2024.101654

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 54

  1. Rts, 2015, Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial, Lancet, 386, 31, 10.1016/S0140-6736(15)60721-8 · DOI
  2. Datoo, 2024, Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial, Lancet, 403, 533, 10.1016/S0140-6736(23)02511-4 · DOI
  3. Dicko, 2023, Seasonal vaccination with RTS,S/AS01(E) vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial, Lancet Infect. Dis., 24, 75, 10.1016/S1473-3099(23)00368-7 · DOI
  4. Chandramohan, 2021, Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention, N. Engl. J. Med., 385, 1005, 10.1056/NEJMoa2026330 · DOI · Paper page
  5. Meremikwu, 2012, Intermittent preventive treatment for malaria in children living in areas with seasonal transmission, Cochrane Database Syst. Rev., 2012
  6. Topazian, 2023, Modelling the relative cost-effectiveness of the RTS,S/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis, Vaccine, 41, 3215, 10.1016/j.vaccine.2023.04.011 · DOI
  7. Draper, 2018, Malaria Vaccines: Recent Advances and New Horizons, Cell Host Microbe, 24, 43, 10.1016/j.chom.2018.06.008 · DOI
  8. Wright, 2014, Plasmodium falciparum erythrocyte invasion: combining function with immune evasion, PLoS Pathog., 10, 10.1371/journal.ppat.1003943 · DOI
  9. Douglas, 2011, The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody, Nat. Commun., 2, 601, 10.1038/ncomms1615 · DOI
  10. Ragotte, 2020, The RH5-CyRPA-Ripr Complex as a Malaria Vaccine Target, Trends Parasitol., 36, 545, 10.1016/j.pt.2020.04.003 · DOI
  11. Scally, 2022, PCRCR complex is essential for invasion of human erythrocytes by Plasmodium falciparum, Nat. Microbiol., 7, 2039, 10.1038/s41564-022-01261-2 · DOI
  12. Farrell, 2023, The PfRCR complex bridges malaria parasite and erythrocyte during invasion, Nature, 625, 578, 10.1038/s41586-023-06856-1 · DOI · Paper page
  13. Crosnier, 2011, Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum, Nature, 480, 534, 10.1038/nature10606 · DOI
  14. Volz, 2016, Essential Role of the PfRh5/PfRipr/CyRPA Complex during Plasmodium falciparum Invasion of Erythrocytes, Cell Host Microbe, 20, 60, 10.1016/j.chom.2016.06.004 · DOI
  15. Galaway, 2019, Resurrection of the ancestral RH5 invasion ligand provides a molecular explanation for the origin of P. falciparum malaria in humans, PLoS Biol., 17, 10.1371/journal.pbio.3000490 · DOI
  16. Douglas, 2015, A PfRH5-Based Vaccine Is Efficacious against Heterologous Strain Blood-Stage Plasmodium falciparum Infection in Aotus Monkeys, Cell Host Microbe, 17, 130, 10.1016/j.chom.2014.11.017 · DOI
  17. Payne, 2017, Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions, JCI Insight, 2, 10.1172/jci.insight.96381 · DOI
  18. Silk, 2023, Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults, Méd., 4, 668
  19. Jin, 2018, Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells, NPJ Vaccines, 3, 32, 10.1038/s41541-018-0071-7 · DOI
  20. Minassian, 2021, Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination, Méd., 2, 701
  21. Silk, 2024, Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial, Lancet Infect. Dis., 10.1016/S1473-3099(24)00312-8 · DOI
  22. Douglas, 2019, A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates, Nat. Commun., 10, 1953, 10.1038/s41467-019-09894-4 · DOI
  23. Foquet, 2018, Plasmodium falciparum Liver Stage Infection and Transition to Stable Blood Stage Infection in Liver-Humanized and Blood-Humanized FRGN KO Mice Enables Testing of Blood Stage Inhibitory Antibodies (Reticulocyte-Binding Protein Homolog 5) In Vivo, Front. Immunol., 9, 524, 10.3389/fimmu.2018.00524 · DOI
  24. Brune, 2016, Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization, Sci. Rep., 6, 10.1038/srep19234 · DOI
  25. Brune, 2018, New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue, Front. Immunol., 9, 1432, 10.3389/fimmu.2018.01432 · DOI
  26. Marini, 2019, A Universal Plug-and-Display Vaccine Carrier Based on HBsAg VLP to Maximize Effective Antibody Response, Front. Immunol., 10, 10.3389/fimmu.2019.02931 · DOI
  27. Meireles, 2015, Three decades of hepatitis B control with vaccination, World J. Hepatol., 7, 2127, 10.4254/wjh.v7.i18.2127 · DOI
  28. Wright, 2014, Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies, Nature, 515, 427, 10.1038/nature13715 · DOI
  29. Hjerrild, 2016, Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system, Sci. Rep., 6, 10.1038/srep30357 · DOI
  30. Jin, 2017, Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal 'C-tag, Int. J. Parasitol., 47, 435, 10.1016/j.ijpara.2016.12.001 · DOI
  31. Campeotto, 2017, One-step design of a stable variant of the malaria invasion protein RH5 for use as a vaccine immunogen, Proc. Natl. Acad. Sci. USA, 114, 998, 10.1073/pnas.1616903114 · DOI
  32. Alanine, 2019, Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies, Cell, 178, 216, 10.1016/j.cell.2019.05.025 · DOI
  33. Douglas, 2014, Neutralization of Plasmodium falciparum Merozoites by Antibodies against PfRH5, J. Immunol., 192, 245, 10.4049/jimmunol.1302045 · DOI
  34. Galaway, 2017, P113 is a merozoite surface protein that binds the N terminus of Plasmodium falciparum RH5, Nat. Commun., 8, 10.1038/ncomms14333 · DOI
  35. Campeotto, 2020, The Structure of the Cysteine-Rich Domain of Plasmodium falciparum P113 Identifies the Location of the RH5 Binding Site, mBio, 11, 10.1128/mBio.01566-20 · DOI
  36. Bullen, 2022, The Plasmodium falciparum parasitophorous vacuole protein P113 interacts with the parasite protein export machinery and maintains normal vacuole architecture, Mol. Microbiol., 117, 1245, 10.1111/mmi.14904 · DOI
  37. Triglia, 2023, Plasmepsin X activates the PCRCR complex of Plasmodium falciparum by processing PfRh5 for erythrocyte invasion, Nat. Commun., 14, 2219, 10.1038/s41467-023-37890-2 · DOI
  38. Jamwal, 2023, Erythrocyte invasion-neutralising antibodies prevent Plasmodium falciparum RH5 from binding to basigin-containing membrane protein complexes, Elife, 12, 10.7554/eLife.83681 · DOI
  39. Olshefsky, 2022, Engineering Self-Assembling Protein Nanoparticles for Therapeutic Delivery, Bioconjugate Chem., 33, 2018, 10.1021/acs.bioconjchem.2c00030 · DOI
  40. Mohsen, 2022, Virus-like particle vaccinology, from bench to bedside, Cell. Mol. Immunol., 19, 993, 10.1038/s41423-022-00897-8 · DOI
  41. Mangold, 1993, Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein, J. Virol., 67, 4588, 10.1128/jvi.67.8.4588-4597.1993 · DOI
  42. Heppner, 2005, Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research, Vaccine, 23, 2243, 10.1016/j.vaccine.2005.01.142 · DOI
  43. Ubillos, 2018, Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children, BMC Med., 16, 197, 10.1186/s12916-018-1186-4 · DOI
  44. Ragotte, 2022, Heterotypic interactions drive antibody synergy against a malaria vaccine candidate, Nat. Commun., 13, 933, 10.1038/s41467-022-28601-4 · DOI
  45. Rijal, 2019, Therapeutic Monoclonal Antibodies for Ebola Virus Infection Derived from Vaccinated Humans, Cell Rep., 27, 172, 10.1016/j.celrep.2019.03.020 · DOI
  46. Wrammert, 2008, Rapid cloning of high-affinity human monoclonal antibodies against influenza virus, Nature, 453, 667, 10.1038/nature06890 · DOI
  47. Varadi, 2022, AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models, Nucleic Acids Res., 50, D439, 10.1093/nar/gkab1061 · DOI · Paper page
  48. Meng, 2023, UCSF ChimeraX: Tools for Structure Building and Analysis, Protein Sci. : a publication of the Protein Society, 32, 10.1002/pro.4792 · DOI
  49. Barrett, 2023, Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype, bioRxiv
  50. Miura, 2008, Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines, Vaccine, 26, 193, 10.1016/j.vaccine.2007.10.064 · DOI
  51. Williams, 2012, Enhancing Blockade of Plasmodium falciparum Erythrocyte Invasion: Assessing Combinations of Antibodies against PfRH5 and Other Merozoite Antigens, PLoS Pathog., 8, 10.1371/journal.ppat.1002991 · DOI
  52. Malkin, 2005, Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria, Infect. Immun., 73, 3677, 10.1128/IAI.73.6.3677-3685.2005 · DOI
  53. Miura, 2008, Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination, J. Immunol., 181, 8776, 10.4049/jimmunol.181.12.8776 · DOI
  54. Willcox, 2021, Antibodies from malaria-exposed Malians generally interact additively or synergistically with human vaccine-induced RH5 antibodies, Cell Rep. Med., 2

Metadata

Authors
King, L. D. W., Pulido, D., Barrett, J. R., Davies, H., Quinkert, D., Lias, A. M., Silk, S. E., Pattinson, D. J., Diouf, A., Williams, B. G., McHugh, K., Rodrigues, A., Rigby, C. A., Strazza, V., Suurbaar, J., Rees-Spear, C., Dabbs, R. A., Ishizuka, A. S., Zhou, Y., Gupta, G., Jin, J., Li, Y., Carnrot, C., Minassian, A. M., Campeotto, I., Fleishman, S. J., Noe, A. R., MacGill, R. S., King, C. R., Birkett, A. J., Soisson, L. A., Long, C. A., Miura, K., Ashfield, R., Skinner, K., Howarth, M. R., Biswas, S., & Draper, S. J.
Affiliations
  • University of Oxford (GB)
  • National Institute of Allergy and Infectious Diseases (US)
  • University of Ghana (GH)
  • Novavax (Sweden) (SE)
  • Weizmann Institute of Science (IL)
  • Leidos (United States) (US)
  • Program for Appropriate Technology in Health (US)
  • United States Agency for International Development (US)
Corresponding author
Draper, Simon J.
ORCID
Venue
Cell Reports Medicine
Publisher
Elsevier BV
Published
2024-07
Volume
5
Issue
7
Pages
101654
ISSN
2666-3791 (ISSN-L)
DOI
10.1016/j.xcrm.2024.101654
PMC
PMC11293324
OpenAlex
W4400683710
Cited by
27
References
1
Citations by year
2026: 9 · 2025: 12 · 2024: 6
FWCI
11.18
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Reports Medicine (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Repository@Nottingham (University of Nottingham) (submittedVersion)
Funders
  • United States Agency for International Development (GH-BAA-2018-Addendum03, 7200AA20C00017)
  • NHS Blood and Transplant
  • Wellcome Trust (106917/Z/15/Z, 205981/Z/17/Z, Z/17/Z, DEL‐15‐007, /Z/15/Z)
  • Novavax
  • Leidos
  • National Institute for Health and Care Research
  • Department of Health and Social Care
  • University of Oxford
  • European Commission (EDCTP2-programme, EDCTP2, 733273, HORIZON2020)
  • African Academy of Sciences (DEL-15–007)
  • National Institutes of Health (00001)
  • Medical Research Council (MR/N013468/1, MC_PC_15040, MR/N013468/, MR/P001351/1)
  • National Institute of Allergy and Infectious Diseases
  • NHLBI Division of Intramural Research
  • European and Developing Countries Clinical Trials Partnership (EDCTP2)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords
RH5, Plasmodium falciparum, blood-stage malaria vaccine, virus-like particles, hepatitis B surface antigen, SpyTag/SpyCatcher, Matrix-M adjuvant, intrinsically disordered regions, vaccine immunogenicity
MeSH terms
Animals, Antibodies, Protozoan, Antigens, Protozoan, Carrier Proteins, Female, Humans, Mice, Inbred BALB C, Plasmodium falciparum, Protozoan Proteins, Malaria, Falciparum, Malaria Vaccines, Mice, Rats, Vaccines, Virus-Like Particle

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review